Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
The fast-spreading Omicron subvariant XBB.1.5 is estimated to account for 43% of the COVID-19 cases in the United States for the week ended Jan. 14, data from the CDC showed.
China s CanSino Biologics Inc has entered test production phase for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account.